What is the FDA status of enobosarm for obesity treatment?

Reviewed by Yoshinori Abe, MD

Internal Medicine

Enobosarm is not currently FDA-approved for the treatment of obesity. While clinical research has explored its potential to preserve lean muscle mass during weight loss, it remains an investigational drug and is not available as an approved obesity therapy in the United States.

If you're concerned about weight changes, muscle loss, or related symptoms, understanding the underlying cause is the critical first step before considering any treatment. Rather than guessing or self-diagnosing, take a free, instant, AI-powered symptom check to clarify what may be driving your symptoms and get guidance on the right next steps to discuss with your doctor.

Reviewed for medical accuracy: 07/20/2026

What brings you in today?

Can I treat this myself Do I need to see a doctor Where should I go for care I'm concerned about a symptom Concerned about a possible condition My symptoms are getting worse Seeking a second opinion

Not seeing your question? No worries.

Submit your own Question

Explanation

Enobosarm is a selective androgen receptor modulator (SARM) that has been studied for various uses, but there is no information in the provided references about its approval by the FDA for obesity treatment.

Clinical study designs for enobosarm have been discussed, but they do not mention obesity as a primary focus. Some discussions talk about selective androgen receptor modulators like enobosarm as potential future treatments, but without specifying FDA approval for obesity. Additionally, there have been reports highlighting cases of liver injury linked to enobosarm, suggesting that safety concerns may exist.

Thus, based on the available references, enobosarm is not approved by the FDA for obesity treatment. If you're experiencing symptoms or health concerns related to weight management, consider using a free symptom checker to better understand your condition. Further research and clinical trials would be needed to evaluate its safety and efficacy for this purpose.

(References)

Crawford J, Prado CM, Johnston MA, Gralla RJ, Taylor RP, Hancock ML, & Dalton JT. (2016). Study Design and Rationale for the Phase 3 Clinical .... Current Oncology Reports, 4853438.
Christiansen AR, Lipshultz LI, Hotaling JM, & Pastuszak AW. (2020). Selective androgen receptor modulators: the future of .... Translational Andrology and Urology, 7108998.
Weinblatt D, & Roy S. (2022). Drug-Induced Liver Injury Secondary to Enobosarm. Journal of Medical Cases, 9119364.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.